Brain

14th Annual Nikon Small World in Motion Competition Winner Captures Embryonic Development in Fruit Flies

Detailing the intricate process of early embryogenesis, this year's winning video provides insights into fundamental biological processes with far-reaching implications.…

1 year ago

CBD Life Sciences, Inc. Unveils Groundbreaking Nutritional Supplement Infused With Mushroom Extracts, Set to Drive Revenue and Revolutionize Wellness

Projected to increase company revenue by 20% in the first year, capitalizing on the booming $18 billion wellness market.SCOTTSDALE, AZ…

1 year ago

Game changer: New 7T MRI elevates Auburn University research

AUBURN, Ala., Sept. 16, 2024 /PRNewswire/ -- Gopikrishna Deshpande wants to see the brain in action. How does information between…

1 year ago

Darmiyan, Inc. Announces Launch of Groundbreaking BrainSee Platform for Alzheimer’s Testing

SAN FRANCISCO, Sept. 16, 2024 /PRNewswire/ -- Darmiyan, Inc., a pioneer in brain technology, is proud to announce the launch…

1 year ago

Penumbra Receives CE Mark for Computer Assisted Vacuum Thrombectomy Technologies – Lightning Flash™ 2.0 and Lightning Bolt™ 7 – in Europe

Latest computer assisted vacuum thrombectomy (CAVT) technologies combine superior catheter design with the latest dual clot detection computer algorithms designed…

1 year ago

Masimo Shares Final Thoughts Ahead of September 19 Annual Meeting Where Everything is at Stake

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), a global leader in noninvasive monitoring technologies and audio products,…

1 year ago

Masimo Partners with Qualcomm to Develop Next-Generation Smartwatch Reference Platform for Original Equipment Manufacturers

Comprehensive Platform Combines Masimo’s Industry-leading Biosensing Capabilities with Snapdragon Wearable Platforms to Expand the Wear OS by Google™ Ecosystem IRVINE,…

1 year ago

Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024

Updated data show consistent objective response rate of 40% and manageable safety profile in patients with non-small cell lung cancer…

1 year ago

RYBREVANT®▼ (amivantamab) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer

Post-progression outcomes showed significant and sustained improvement for amivantamab plus chemotherapy versus chemotherapy alone1 BEERSE, BELGIUM , Sept. 14, 2024…

1 year ago